There is a lot of variation in how patients with acute myeloid leukemia (AML) react to the disease, and to its treatment. There are three main approaches to managing AML, and assessing the risks and benefits of each approach is crucial for making treatment decisions. Risk stratification involves assessing a patient’s age, health, and overall underlying conditions.
Mikkael Sekeres, MD, director of the Leukemia Program and vice-chair for Clinical Research at the Cleveland Clinic Taussig Cancer Institute, discusses a phase 2 study of pevonedistat plus azacitidine…
Cristina Papayannidis, MD, PhD, University of Bologna, Bologna, Italy, discusses a study evaluating the efficacy of combining venetoclax with hypomethylating agents in treating patients with acute myeloid leukemia…
Naval Daver, MD, University of Texas MD Anderson Cancer Center, shares recent work on combination magrolimab, a CD47-targeting monoclonal antibody, and the hypomethylating agent azacitidine. The azacitidine and…
Alice S. Mims, MD, of The Ohio State University’s James Comprehensive Cancer Center, provided an overview of current AML treatment options, such as FLT3 and IDH inhibitors, while…
Naval G. Daver, MD, an associate professor in the Department of Leukemia, Division of Cancer Medicine at the University of Texas MD Anderson Cancer Center, highlights findings from the randomized phase…
Naval G. Daver, MD, associate professor in the Department of Leukemia at The University of Texas MD Anderson Cancer Center, explains the results of a phase 1 trial…
